Free Trial

Hikma Pharmaceuticals (HIK) Competitors

GBX 1,880
+13.00 (+0.70%)
(As of 12:04 PM ET)

HIK vs. HCM, INDV, AMYT, BMK, AGY, APH, BXP, ANCR, EAH, and DNL

Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Benchmark (BMK), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), ECO Animal Health Group (EAH), and Diurnal Group (DNL). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Hikma Pharmaceuticals vs.

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking.

Hikma Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

HUTCHMED has a net margin of 12.03% compared to Hikma Pharmaceuticals' net margin of 6.61%. HUTCHMED's return on equity of 14.65% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals6.61% 8.81% 8.46%
HUTCHMED 12.03%14.65%0.99%

In the previous week, Hikma Pharmaceuticals' average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Hikma Pharmaceuticals Neutral
HUTCHMED Neutral

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£2.88B1.45£190M£0.672,803.39
HUTCHMED£838M3.08£100.78M£0.103,020.00

Hikma Pharmaceuticals received 603 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.58% of users gave Hikma Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Hikma PharmaceuticalsOutperform Votes
799
70.58%
Underperform Votes
333
29.42%
HUTCHMEDOutperform Votes
196
78.40%
Underperform Votes
54
21.60%

37.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 35.4% of HUTCHMED shares are held by institutional investors. 30.6% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 42.9% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals presently has a consensus price target of GBX 2,225, indicating a potential upside of 19.18%. Given Hikma Pharmaceuticals' higher possible upside, equities analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Hikma Pharmaceuticals beats HUTCHMED on 8 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIK vs. The Competition

MetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£4.17B£1.19B£4.91B£1.40B
Dividend Yield2.93%3.07%5.25%11.82%
P/E Ratio2,803.39318.72148.291,694.12
Price / Sales1.455,602.042,259.19294,583.34
Price / Cash8.3410.0933.7232.87
Price / Book1.895.554.852.78
Net Income£190M£148.96M£105.58M£165.77M
7 Day Performance2.25%1,727.85%118.11%0.38%
1 Month Performance-4.70%1,949.80%129.69%1.15%
1 Year Performance-7.93%2,115.97%132.09%18.83%

Hikma Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
0 of 5 stars
0.00 / 5 stars
GBX 293
-1.0%
N/A+46.5%£2.50B£838M2,930.001,988
INDV
Indivior
1.3918 of 5 stars
1.39 / 5 stars
GBX 793
-2.0%
GBX 2,100
+164.8%
-57.9%£1.07B£1.12B26,433.331,000Gap Down
AMYT
Amryt Pharma
0 of 5 stars
0.00 / 5 stars
GBX 143
-11.7%
N/A+0.0%£457.11M£210.24M-4.33290Gap Down
BMK
Benchmark
0 of 5 stars
0.00 / 5 stars
GBX 38.70
+0.1%
N/A-4.2%£286.28M£155.53M-1,290.00823Gap Down
AGY
Allergy Therapeutics
0 of 5 stars
0.00 / 5 stars
GBX 5.60
+1.8%
N/A+173.2%£267.12M£53.26M-93.33612News Coverage
APH
Alliance Pharma
2.2252 of 5 stars
2.23 / 5 stars
GBX 36.70
+0.5%
GBX 56.50
+54.0%
-23.5%£198.33M£170.05M-3,670.00285Gap Down
BXP
Beximco Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
GBX 38.50
flat
N/A+5.5%£171.75M£43.08B481.25780Gap Down
ANCR
Animalcare Group
0 of 5 stars
0.00 / 5 stars
GBX 244
+3.0%
N/A+42.3%£147.30M£74.35M12,200.00220Positive News
EAH
ECO Animal Health Group
0 of 5 stars
0.00 / 5 stars
GBX 114
-1.7%
N/A+2.2%£77.22M£88.46M-5,700.00234
DNL
Diurnal Group
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£46.33M£4.68M-3.2133

Related Companies and Tools

This page (LON:HIK) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners